Copy Link Print Information

IGFBP-2 Protein, Human (HEK293, His)

2 Cited Publications
Customer Review

Based on 2 publication(s) in Google Scholar

IGFBP2 Protein, Human (HEK293, His) is a member of the family of high-affinity binding proteins (IGFBP1-6) and appears to play a governing role in Insulin-like Growth Factor (IGF) regulation in the central nervous system.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Experimental Validation Results for IGFBP-2 Protein, Human (HEK293, His)
  • Experimental Validation Results for IGFBP-2 Protein, Human (HEK293, His)
  • IGFBP-2 Protein, Human (HEK293, His) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Biological Activity

Description

IGFBP2 Protein, Human (HEK293, His) is a member of the family of high-affinity binding proteins (IGFBP1-6) and appears to play a governing role in Insulin-like Growth Factor (IGF) regulation in the central nervous system.

Background

Insulin-like Growth Factor Binding Protein 2 (IGFBP2) is a member of the family of high-affinity binding proteins (IGFBP1-6) and appears to play a governing role in Insulin-like Growth Factor (IGF) regulation in the central nervous system[1]. Insulin-like Growth Factor-Binding Proteins (IGFBPs) modulate the actions of secreted insulin-like growth facts (IGFs) by binding to them and increase the IGF halflife in the extracellular milieu and circulation by sequestering them in this bound form. IGFBPs either enhance or inhibit IGF actions on target cells; the individual IGFBPs either inhibit or potentiate IGF effects on osteoblasts in bone[2].

Verified Bioactivity

1. The ED50 is <2 µg/mL as measured by FDC-P1 cells.
2. Measured by its ability to inhibit the biological activity of IGF-II on MCF-7 human breast cancer cells. The ED50 for this effect is 0.05-0.2 μg/ml in the presence of 14 ng/mL rhIGF-II.

MCE Validation Data

  • Purity - SDS-PAGE

    Purity - SDS-PAGE

    ≥ 95%, as determined by reducing SDS-PAGE.

  • Bioactivity - Cell-Based Assay

    Bioactivity - Cell-Based Assay

    Measured by its ability to inhibit the biological activity of IGF-II on MCF-7 human breast cancer cells. The ED50 for this effect is 0.1501 μg/mL in the presence of 14 ng/mL rhIGF-II, corresponding to a specific activity is 6.662×103 units/mg.

Technical Parameters

  • Species Human
  • Source HEK293
  • Tag C-His
  • Accession

    P18065 (F40-Q325)

  • Gene ID
    3485  [NCBI]
  • Molecular Construction
    • N-term
    • IGFBP-2 (F40-Q325)
      Accession # P18065
    • His
    • C-term
  • Protein Length

    Full Length of Insulin-like growth factor-binding protein 2 Chain

  • Synonyms

    IGFBP2; Insulin-Like Growth Factor Binding Protein 2 (36kD); Prev. IBP2; IGF-BP53; Insulin-Like Growth Factor-Binding Protein 2; IGFBP-2; Insulin-Like Growth Factor Binding Protein 2, 36kDa; IBP-2; IGF-Binding Protein 2; BP2; Insulin Like Growth Factor Bi

  • AA Sequence

    FRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ

  • Predicted Molecular Mass

    31.9 kDa

  • Molecular Weight

    Approximately 31 kDa, based on SDS-PAGE under reducing conditions.

  • Glycosylation

    Yes

  • Purity

    ≥ 95%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder

Formulation

1.Lyophilized from a 0.2 μm filtered solution of PBS.
2.Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

References

[1]. Milanesi E, et al. Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. World J Biol Psychiatry. 2018 Dec;19(8):610-618. [Content Brief]

[2]. Richman C, et al. Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. Endocrinology. 1999 Oct;140(10):4699-705. [Content Brief]

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedChemExpress Validation
     ≥ 95%, as determined by reducing SDS-PAGE.

  • 1/16

    MedChemExpress Validation
     Measured by its ability to inhibit the biological activity of IGF-II on MCF-7 human breast cancer cells. The ED50 for this effect is 0.1501 μg/mL in the presence of 14 ng/mL rhIGF-II, corresponding to a specific activity is 6.662×103 units/mg.

  • IGFBP-2 Protein, Human (HEK293, His) Product Image
    1/16
  • Experimental Validation Results for IGFBP-2 Protein, Human (HEK293, His)
  • Experimental Validation Results for IGFBP-2 Protein, Human (HEK293, His)
  • IGFBP-2 Protein, Human (HEK293, His) Product Image